The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.
The current medications composing HCV combination therapy are being challenged by Valeant Pharmaceuticals. A recent study reported that HCV therapy with interferon and Viramidine® has fewer side effects than today's standard combination therapy.
Continue reading »Scientists have discovered a protein necessary for liver cell regeneration, an ability that is directly impacted by liver disease. The identification of this protein in helping the liver to heal itself opens up a new realm of liver disease treatment possibilities.
Continue reading »Magnetic Resonance Imaging (MRI) technology can now help detect end stage liver disease. Needle biopsies will quickly become archaic as this painless, low-risk and accurate method continues to demonstrate promise in evaluating liver fibrosis.
Continue reading »Results of a Phase II study indicate that the oral medication Suvus (TM) can significantly lower HCV viral load without any major side effects. Because it was only tested to battle HCV genotype 4a, this medication may not directly benefit those with other HCV genotypes. However, hope lies in the fact that progress is being made against the virus as a whole, with new breakthroughs occurring every day.
Continue reading »Researchers have uncovered a gene capable of preventing HCV replication. With modern technology's ability to use genetic microbiology in the fight against disease, this discovery could lead to viable treatment developments for Hepatitis C.
Continue reading »A novel approach to hepatitis C treatment will be presented at this year's annual meeting of the American Association of Liver Diseases. The preliminary results for a new class of drug designed to destroy both HCV viral particles and HCV infected cells show great promise. Bavituximab's recognition at this high-profile and well-respected event signifies this drug's potential.
Continue reading »Two companies committed to finding a vaccine for hepatitis C have released encouraging news on their progress. Tripep and Inovio's efforts to introduce a genetically engineered medicine through a patented DNA delivery system appear to stimulate immunity against Hepatitis C. As it evolves, this technology represents great hope for controlling the spread of the Hepatitis C virus.
Continue reading »One-third of all HIV positive patients are also infected with the hepatitis C virus. A new diagnostic test allows physicians to quickly identify both viruses with a single blood sample. With this diagnostic tool, doctors can immediately begin tailoring a comprehensive treatment plan.
Continue reading »The preliminary results from the Phase 1b study of a compound taken in conjunction with pegylated interferon are expected later this month. This proof of concept milestone indicates progress toward a feasible and functional Hepatitis C treatment. The next step is a Phase 2 trial. We will be anxiously awaiting the results and will report them to you as soon as have them.
Continue reading »By replacing ribavarin with anti-cholesterol medications, researchers of a recent study improved the effectiveness of combination therapy in preventing the replication of the hepatitis C virus. This is welcome news, particularly to the 45% of chronic hepatitis C patients who do not respond to current combination therapy.
Continue reading »Inside you'll discover:
You'll also receive the latest news and information to support liver health.
Rest assured, we will not rent your email to anyone.
You should receive your email with links to the reports shortly. If you do not, please check your spam/junk folder.
If you still haven't received our email after a few minutes, please feel free to contact us.
Close Window
